TY - JOUR. T1 - Epstein-barr-virus-related malignant b cell lymphoplasmacytic lymphoma following allogeneic bone marrow transplantation for aplastic anemia. AU - Forman, Stephen J.. AU - Sullivan, John L.. AU - Wright, Christine. AU - Ratech, Howard. AU - Racklin, Barbara. AU - Blume, Karl G.. PY - 1987. Y1 - 1987. N2 - The development of B cell lymphoma has been reported to occur in recipients of a variety of organ transplants, including some patients who have received an allogeneic bone marrow graft. In this report, we describe a patient with severe aplastic anemia who developed a malignant B cell lymphoplasmacytoid proliferation 48 days after undergoing allogeneic marrow transplantation from her HLA-matched MLC-nonreactive brother. Immunologic studies showed this malignancy to be a mixed polyclonal and monoclonal proliferation in donor ceils. Virologie studies documented Epstein Bare infection of the cells. A review of the literature suggests that graft-versus-host disease and treatment of ...
View the Pediatric Bone Marrow Transplantation Program statistics for St. Louis Childrens Hospital including number of procedures, statistics for both autologous and allogeneic patients and survivor ratings. For more information on the Pediatric Bone Marrow Transplant Program, call 314-454-KIDS (5437).
TY - JOUR. T1 - Chemotherapy vs HLA-identical sibling bone marrow transplants for adults with acute lymphoblastic leukemia in first remission. AU - Oh, H.. AU - Gale, R. P.. AU - Zhang, M. J.. AU - Passweg, J. R.. AU - Ino, T.. AU - Murakami, H.. AU - Ohno, R.. AU - Rowlings, P. A.. AU - Sobocinski, K. A.. AU - Tanimoto, M.. AU - Tomonaga, M.. AU - Weisdorf, D. J.. AU - Horowitz, M. M.. PY - 1998. Y1 - 1998. N2 - There is controversy about whether chemotherapy or an HLA-identical sibling bone marrow transplant is better treatment for adults with acute lymphoblastic leukemia (ALL) in first remission. A previous study of patients treated in 1980-1987 showed similar leukemia-free survivals with these approaches. We re-examined this issue in more recently treated patients receiving different chemotherapy. Chemotherapy subjects (n = 76) participated in trial ALL-87 of the Japan Adult Leukemia Study Group (JALSG). Transplant subjects (n = 214) were reported to the International Bone Marrow Transplant ...
Epstein-Barr virus-associated lymphoproliferative disorder after autologous bone marrow transplantation: report of two cases. Hauke, R.J.; Greiner, T.C.; Smir, B.N.; Vose, J.M.; Tarantolo, S.R.; Bashir, R.M.; Bierman, P.J. // Bone Marrow Transplantation;6/15/98, Vol. 21 Issue 12, p1271 Epstein-Barr virus-associated lymphoproliferative disorders have been frequently reported as a complication of solid organ and allogeneic bone marrow transplantation. Their occurrence is rare after autologous bone marrow transplantation (BMT) with only five published reports in the literature.... ...
TY - JOUR. T1 - Bone marrow engraftment and GVHD following bone marrow transplantation across a concordant xenogeneic barrier (mouse to rat). AU - Li, H.. AU - Selvaggi, G.. AU - Ricordi, C.. AU - Inverardi, L.. PY - 1997/7/7. Y1 - 1997/7/7. UR - http://www.scopus.com/inward/record.url?scp=0030979295&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0030979295&partnerID=8YFLogxK. U2 - 10.1016/S0041-1345(97)00288-1. DO - 10.1016/S0041-1345(97)00288-1. M3 - Article. C2 - 9193584. AN - SCOPUS:0030979295. VL - 29. SP - 2190. EP - 2191. JO - Transplantation Proceedings. JF - Transplantation Proceedings. SN - 0041-1345. IS - 4. ER - ...
TY - JOUR. T1 - Hepatitis C virus (HCV) infection in bone marrow transplant patients after transfusions from anti-HCV-positive blood donors. AU - Shuhart, M. C.. AU - Myerson, D.. AU - Spurgeon, C. L.. AU - Bevan, C. A.. AU - Sayers, M. H.. AU - McDonald, G. B.. PY - 1996/4/1. Y1 - 1996/4/1. N2 - In March 1992, 12 bone marrow transplant patients at the Fred Hutchinson Cancer Research Center received blood components from donors who were anti-HCV-nonreactive by first generation ELISA but whose serum later tested anti-HCV-reactive to a second generation ELISA. All these blood components were further tested for anti-HCV using a second-generation RIBA and for HCV RNA by polymerase chain reaction. Recipient sera were tested for HCV RNA prior to and following blood component infusion. Blood components from four donors were positive for HCV RNA. All recipients of HCV RNA-positive blood components became viremic on the first day tested post-infusion. In addition, two recipients of HCV RNA-negative blood ...
TY - JOUR. T1 - Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. AU - Frassoni, Francesco. AU - Labopin, Myriam. AU - Powles, Ray. AU - Mary, Jean Yves. AU - Arcese, William. AU - Bacigalupo, Andrea. AU - Bunjes, Donald. AU - Gluckman, Eliane. AU - Ruutu, Tapani. AU - Schaefer, Ulrich W.. AU - Sierra, Jorge. AU - Vernant, Jean Paul. AU - Willemze, Roel. AU - De Witte, Theo. AU - Gorin, Norbert Claude. PY - 2000/4/22. Y1 - 2000/4/22. N2 - Background: There is increasing pressure for the recognition and replication of good clinical practice. We undertook a study to assess the variability in outcome of allogeneic bone-marrow transplantation among major European centres. Methods: We studied 13 centres, including 522 patients (aged 16-55 years), which had undertaken more than 30 bone-marrow transplantations between Jan 1, 1987, and Dec 31, 1995, for acute myeloid leukaemia in first complete remission. We undertook a (global) multivariate analysis of all factors ...
Gonadal function after allogenic bone marrow transplantation for thalassaemia. Social integration of the older thalassaemic patient
We discuss clinical strategies for the prophylaxis and treatment of both acute and chronic graft-versus-host disease (GVHD) with particular attention to children. Grades II to IV acute GVHD occur in 10 to 50% of patients given an allogeneic transplantation of haemopoietic stem cells (HSCT) from a genotypically HLA-identical donor. A significantly higher incidence and severity of the disease is reported in patients receiving transplants from partially matched family donors or unrelated volunteers. Younger individuals or patients receiving HSCT from younger donors develop GVHD less frequently than do older recipients. Severe acute GVHD is characterised by a significant decrease in survival probability, even though the graft-versus-leukaemia activity associated with both acute and chronic GVHD may reduce the risk of leukaemia relapse. Prophylaxis of acute GVHD usually consists of in vivo post-grafting immunosuppression with cyclosporin alone or in combination with methotrexate; methotrexate alone ...
RATIONALE: Giving chemotherapy and total-body irradiation before a donor bone marrow transplant or peripheral blood stem cell transplant helps stop the growth of cancer and abnormal cells and helps stop the patients immune system from rejecting the donors stem cells. When certain stem cells from a donor are infused into the patient they may help the patients bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the bodys normal cells. Removing the T cells from the donor cells before transplant may stop this from happening.. PURPOSE: This randomized phase III trial is studying donor bone marrow that is treated in the laboratory using two different devices to compare how well they work in treating patients who are undergoing a donor bone marrow transplant for hematologic cancer. ...
Intensive, myelosuppressive therapy is necessary to maximize outcomes for patients with acute myeloid leukemia (AML). A comparison was made of 3 aggressive postremission approaches for children and adolescents with AML in a randomized trial, CCG-2891. A total of 652 children and adolescents with AML who achieved remission on 2 induction regimens using identical drugs and doses (standard and intensive timing) were eligible for allocation to allogeneic bone marrow transplantation (BMT) based on matched related donor status (n = 181) or randomization to autologous BMT (n = 177) or to aggressive high-dose cytarabine-based chemotherapy (n = 179). Only 115 patients (18%) refused to participate in the postremission phase of this study. Overall compliance with the 3 allocated regimens was 90%. At 8 years actuarial, 54% +/- 4% (95% confidence interval) of all remission patients remain alive. Survival by assigned regimen (intent to treat) is as follows: allogeneic BMT, 60% +/- 9%; autologous BMT, 48% ...
different allogeneic graft accelerates white cell and platelet engraftment after T-cell-depleted bone marrow transplantation. Addition of a seconds profile, publications, research topics, and co-authors
TY - JOUR. T1 - A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumors. AU - Adkins, Douglas R.. AU - Irvin, Rebecca. AU - Kuhn, John. AU - Boldt, David H.. AU - Roodman, G. David. AU - Salzman, Donna. AU - Freytes, Cesar. AU - Von Hoff, D. D.. AU - LeMaistre, C. F.. PY - 1993/6. Y1 - 1993/6. N2 - Dacarbazine (DTIC) is a chemotherapy drug which has antitumor activity at standard doses, exhibits a steep dose-response effect in vitro, and is associated with relatively few non-hematologic toxicities. These characteristics suggest a potential role for this drug in bone marrow transplant preparative regimens. To pursue this hypothesis, 16 patients with refractory solid tumors were enrolled in a phase I study of single agent DTIC to determine the dose of DTIC requiring bone marrow reinfusion and to define the dose-limiting toxicity and maximum tolerated dose when given with autologous bone marrow rescue. Pharmacokinetics ...
Invasive mold infections (IMIs) are an important cause of morbidity and mortality in patients who are undergoing bone marrow transplantation (BMT). To examine the epidemiology, risk factors, and outcome of IMIs in allogeneic BMT recipients, all cases of mold infection among 94 adult patients who underwent allogeneic BMT at this institution from 1 January 1997 through 31 December 1998 were reviewed retrospectively. Fifteen cases of IMI were identified; infection occurred a median of 102 days after BMT. Aspergillus species was the most common cause of disease, and species other than Aspergillus fumigatus were present in 53% of patients. By multivariate analysis, the variable associated with infection risk was systemic glucocorticosteroid use. Prophylactic antifungal therapy that was targeted to high-risk patients had little effect on disease incidence. These observations suggest that early identification of high-risk patients and better approaches to prevention should be explored, to reduce ...
Competitive bone marrow transplantation assay measures multi-lineage reconstitution of hematopoiesis in irradiated transplant recipient mice. Thus this assay is routinely used to determine haematopoietic stem and progenitor cells (HSPCs) functionality in vivo. The principle of the method is to transplant bone marrow donor cells (derived from transgenic mice of choice) on C57BL6 background together with normal competitor bone marrow. In order to distinguish donor from competitor cells upon transplantation, usually competitor mice are congenic and carry the differential B cell antigen originally designated Ly5.1 and CD45.1.A typical competitive bone marrow transplantation experiment will contain two transplantation groups, donor (transgenic mice of choice and their controls) are transplanted in competition with normal competitors and engraftment efficiency is evaluated in both blood and bone marrow.
TY - JOUR. T1 - Blood and bone marrow transplantation for acute myeloid leukemia. AU - Villela, Luis M.. AU - Bolanos Meade, F Javier. PY - 2009. Y1 - 2009. N2 - Bone marrow transplantation is the treatment of choice for some patients with acute myeloid leukemia and myelodysplastic syndrome (MDS). Patients with high-risk disease, such as those with MDS, in second (or subsequent) complete remission or those with poor-risk cytogenetics will benefit the most from this approach. With current transplantation techniques, outcomes have improved over recent years. Although relapse and graft-versus-host disease still are important problems faced by these patients, novel approaches have been developed to decrease the risk of complications, with excellent results.. AB - Bone marrow transplantation is the treatment of choice for some patients with acute myeloid leukemia and myelodysplastic syndrome (MDS). Patients with high-risk disease, such as those with MDS, in second (or subsequent) complete remission ...
A healthy immune system produces T cells that can recognize and react against foreign molecules (antigens) to protect against infection, while leaving normal host cells with "self antigens" undamaged. All T cells are produced in the thymus from blood stem cells that originate in the bone marrow and migrate through the blood circulation to the thymus. During aging, the thymus shrinks in size (involutes) and T cell production is limited, causing a poorly functioning immune system. T cell production and immune recovery is also slow and incomplete after bone marrow transplantation in older patients. In previous studies we showed that the thymus grows rapidly and T production is very robust in new-born mice. We also showed that during the new-born period, a growth factor called Vascular Endothelial Growth Factor (VEGF) is made at high levels in the thymus. When VEGF is inhibited in new-borns, T cell production falls, suggesting that this molecule plays an important role in thymic growth during this ...
And after more than 50 years of tireless investigations, this procedure has become standard treatment of hematologic malignancies. Despite major advances, bone marrow transplantation is still a difficult and evolving field. A newly published clinical resource called Clinical Manual of Blood and Bone Marrow Transplantation is a valuable addition to the literature on transplantation. Well-Organized Format EDITED BY Drs. Syed A. Abutalib and Parameswaran Hari, the book provides a concise practical expert review in a well-organized format of 42 chapters, each annotated with numerous practical headings to enhance focused learning. Stem cell transplantation is highly specialized, and this book is targeted for teachers and clinicians in the field. Each of the 42 chapters focuses on a particular topic and provides numerous reference tables and figures. The structure provides a neat and handy compendium for daily work caring for bone marrow transplant patients. It also offers a complete set of ...
OBJECTIVES: I. Compare the disease free survival of patients with leukemia, myelodysplasia, or lymphoblastic lymphoma after treatment with conventional (non-T cell depleted) or T cell depleted unrelated donor bone marrow transplantation. II. Compare the incidence of primary and secondary graft failure, acute and chronic graft-vs-host disease, complications (infection, veno-occlusive disease, interstitial pneumonitis), and relapse in these patients after these treatments. III. Compare the incidence of other malignancies, lymphoproliferative disorders, and post-transplant myelodysplasia in these patients after these treatments.. OUTLINE: This is a randomized, multicenter study. Patients will be stratified according to institution. Patients are assigned to one of two treatment arms, one with conventional bone marrow transplantation (arm I) and one with T cell depletion of the bone marrow (arm II). Arm I: Patients receive cyclophosphamide on days -6 and -5. Total body irradiation (TBI) is ...
TY - JOUR. T1 - Leukocyte low density lipoprotein receptor (LDL-R) does not contribute to LDL clearance in vivo. T2 - Bone marrow transplantation studies in the mouse. AU - Fazio, Sergio. AU - Hasty, Alyssa H.. AU - Carter, Kathy J.. AU - Murray, Alisa B.. AU - Price, James O.. AU - Linton, MacRae R.F.. PY - 1997/2/1. Y1 - 1997/2/1. N2 - The targeted disruption of the low density lipoprotein (LDL) receptor gene in mice results in accumulation of plasma LDL cholesterol and in predisposition to diet-induced aortic atherosclerosis. Although the liver is the central organ for receptor mediated clearance of LDL, the in vivo role of other organs and tissues in LDL catabolism has not been directly studied. Since bone marrow-derived cells such as blood leukocytes and tissue macrophages express LDL receptors and contribute a large cell mass to the body, we designed bone marrow transplantation (BMT) experiments to reconstitute LDL receptor null mice [LDL-R(-/-)] with marrow obtained from LDL-R wild-type ...
The results in 34 adult patients with acute myeloid leukemia (AML) who have undergone autologous bone marrow transplantation (ABMT) using busulfan and cyclophosphamide (Bu/Cy) in 12 United Kingdom (UK) centers have been analyzed. There were 19 females and 15 males; median age was 40 years (range, 21 to 62 years). Nine patients were in first relapse; 25 were in second remission. The median time of first remission for the whole group was 11.5 months (range, 1 to 56 months). All the patients in first relapse and six patients in second remission received first remission marrow. The leukemia-free survival (LFS) for the patients in first relapse was 33%, with a median follow-up of 20 months. The LFS for the patients in second remission was 48% with a median follow-up of 26 months. The length of second remission exceeds the length of first remission in 14 patients. Considerable toxicity with hemorrhagic cystitis (four patients; none fatal), venoocclusive disease (four patients; one fatal), pneumonitis ...
Intravenous literature: Wiersma, P., Schillie, S., Keyserling, H., Watson, J.R., De, A., Banerjee, S.N., Drenzek, C.L., Arnold, K.E., Shivers, C., Kendrick, L., Ryan, L.G., Jensen, B., Noble-Wang, J. and Srinivasan, A. (2010) Catheter-Related Polymicrobial Bloodstream Infections among Pediatric Bone Marrow Transplant Outpatients, Atlanta, Georgia, 2007. Infection Control & Hospital Epidemiology. 31, [ePub ahead of print]. Abstract:. Objective: To identify risk factors for polymicrobial bloodstream infections (BSIs) in pediatric bone marrow transplant (BMT) outpatients attending a newly constructed clinic affiliated with a children’s hospital.. Methods: All 30 outpatients treated at a new BMT clinic during September 10â€"21, 2007, were enrolled in a cohort study. The investigation included interviews, medical records review, observations, and bacterial culture and molecular typing of patient and environmental isolates. Data were analyzed using exact conditional logistic ...
Established in 1911, The University of Tennessee Health Science Center aims to improve human health through education, research, clinical care and public service. The UT Health Science Center campuses include colleges of Dentistry, Graduate Health Sciences, Health Professions, Medicine, Nursing and Pharmacy. Patient care, professional education and research are carried out at hospitals and other clinical sites across Tennessee. Endowed professorships, Research Centers of Excellence, and continuing relationships with research and healthcare facilities across Tennessee ensure that both basic science and applied research stay focused on contemporary health topics.
Pediatr Dent. 1989 Mar;11(1):37-42. Clinical Trial; Controlled Clinical Trial; Research Support, Non-U.S. Govt; Research Support, U.S. Govt, P.H.S.
We analyzed the clinical course and risk factors of 18 patients with poor engraftment after allogeneic bone marrow transplantation (BMT), defined as absolute neutrophil count below 0.1×10 9/1 28 days post-BMT. Significant risks associated with non-engraftment included HLA one antigen mismatch, BMT from matched unrelated donor, and a low dose of colony-forming units-granulocyte-macrophage (,10 4/kg). Examined by a semi-quantitative analysis of polymorphic microsatellite markers, donor DNA chimerism on day 28 was found to be predictive of treatment outcome. Seven patients had detectable donor DNA, varying from 43 to 100%. Five of them responded to granulocyte colony-stimulating factor (G-CSF) and achieved engraftment. Two were given further infusions of peripheral blood hematopoietic stem cells (PBSC) from the same donors, resulting in engraftment in one of them. Eleven patients had no detectable donor DNA, and none responded to G-CSF. Autologous regeneration occurred in six of these patients, ...
Fludarabine is a nucleoside analog with potent antitumor and immunosuppressive properties used in conditioning regimens of pediatric allogeneic hematopoietic cell transplantation (alloHCT) to promote stem cell engraftment.. This is a single-center, pharmacokinetic-pharmacodynamic (PK-PD) study investigating the clinical pharmacology of fludarabine in 45 children undergoing alloHCT at UCSF Benioff Childrens Hospital.. Patients would receive fludarabine regardless of whether or not they decide to consent to PK sampling.. Fludarabine doses will not be adjusted based on PK data.. We will apply the combination of a D-optimality-based limited sampling strategy and population PK methodologies to determine specific factors influencing fludarabine exposure in pediatric alloHCT recipients and identify exposure-response relationships.. Subjects will undergo PK sampling of plasma (f-ara-a) and intracellular (f-ara-ATP) drug concentrations over the duration of fludarabine therapy (3 to 5 days).. To evaluate ...
Question - Successful bone marrow transplant for AML. Now have back pain, cough, loss of appetite. Why?. Ask a Doctor about Bone marrow transplant, Ask an Oncologist
Allogeneic bone marrow transplantation (stem cell transplant) in aplastic anemia (costs for program #80341) ✔ Andreasklinik Cham Zug ✔ Department of Oncology and Hematology ✔ BookingHealth.com
Allogeneic bone marrow transplantation (stem cell transplant) in acute lymphoblastic leukemia (ALL) (costs for program #260823) ✔ University Hospital Münster ✔ Department of Hematology, Hemostaseology, Oncology and Pneumology (Medical Department A) ✔ BookingHealth.com
To determine whether graft-versus-leukemia (GVL) reactions are important in preventing leukemia recurrence after bone marrow transplantation, we studied 2,254 persons receiving HLA-identical sibling bone marrow transplants for acute myelogenous leukemia (AML) in first remission, acute lymphoblastic …
Intensive chemoradiotherapy, with or without additional local radiotherapy, and unpurged autologous marrow transplantation was given to 68 patients with progressive non-Hodgkins lymphoma. Responses were attained in 44 patients (65%, 95% confidence intervals [CI], 52% to 76%), including 37 who achieved complete responses. Fifteen patients (22%, 95% C.I. 13% to 34%) remain free of disease (including 11 continuously) at a median of 5.3 (range 3.1 to 9.1) years later. Higher Karnofsky scores (P less than .01, Mann-Whitney U test) and the absence of a history of prior radiotherapy (P = .02, chi 2 test) were associated with achievement of complete plus partial responses. Higher Karnofsky scores (P less than .01, Mann-Whitney U test) and less resistant disease status at transplantation (P = .04, chi 2 test) were significant when calculations were limited to complete responses. Karnofsky scores were also associated with the probability of freedom from progression (P = .02, log-rank) for responding ...
New research provides preclinical proof-of-concept for the ability of PRO 140, a humanized anti-CCR5 monoclonal antibody under development by CytoDyn Inc., to effectively block the development of graft-versus-host disease, a potentially lethal complication of bone marrow stem cell transplantation. CytoDyn is currently enrolling patients in a Phase 2 clinical trial with PRO 140 for the prevention of GvHD in leukemia patients undergoing BMSC transplantation.
Transplantation of 8 x 10(6) C57BL/6-Nu+/Nu+ (nude) bone marrow cells into C3H/HeJ recipients after conditioning with 8 Gy of total body irradiation has resulted in a markedly higher rate of graft rejection or graft failure compared to that found in recipients of normal C57BL/6 or C57BL/6-Bg+/Bg+ (beige) T-cell-depleted bone marrow. Mixing experiments using different numbers of nude bone marrow cells with or without mature thymocytes (unagglutinated by peanut agglutinin) revealed that engraftment of allogeneic T-cell-depleted bone marrow is T-cell dependent. To ensure engraftment, a large inoculum of nude bone marrow must be supplemented with a trace number of donor T cells, whereas a small bone marrow dose from nude donors requires a much larger number of T cells for engraftment. Marked enhancement of donor type chimerism was also found when F1 thymocytes were added to nude bone marrow cells, indicating that the enhancement of bone marrow engraftment by T cells is not only mediated by ...
TY - JOUR. T1 - Is there a place for autologous bone marrow transplantation in chronic myeloid leukemia?. AU - Frassoni, F.. AU - Carella, A. M.. PY - 1993. Y1 - 1993. UR - http://www.scopus.com/inward/record.url?scp=0027525235&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0027525235&partnerID=8YFLogxK. M3 - Article. C2 - 8298470. AN - SCOPUS:0027525235. VL - 11. SP - 1. EP - 3. JO - Stem Cells. JF - Stem Cells. SN - 1066-5099. IS - SUPPL. 3. ER - ...
Stem Cell Transplantation. Stem cell transplantation, also referred as bone marrow transplantation, is currently being performed in the treatment of leukemia, lymphoma, multiple myeloma, various cancers, poorly functioning bone marrow, hereditary anemia, immunodeficiencies and hereditary metabolic diseases.. Stem cells can be obtained from bone marrow, peripheral blood or cord blood. Although bone marrow has been used historically as a stem cell source in the first transplantations, peripheral blood stem cell transplantation is currently performed in 75% of cases. Stem cell from the cord blood is collected as soon as the baby is born. Collected stem cells are stored in sterile conditions.. Stem cell transplants are defined as autologous or allogeneic transplantation.. Autologous transplantation is the process by which the patients own stem cells are collected and stored frozen, then given back to the patient. The most common uses for autologous stem cell transplantation are solid tumors such as ...
Published in Bone Marrow Transplantation, Volume 21, Issue 5, 1998, pages 461-471. Lamb, Jr., L. S., Gee, A. P., Henslee-Downey, P. J., Geier, S. S., Hazlett, L., Pati, A. R., Godder, K., Abhyankar, S. A., Turner, M. W., Lee, C., Harris, W. G., & Parrish, R. S. (1998). Phenotypic and functional reconstitution of peripheral blood lymphocytes following T cell-depleted bone marrow transplantation from partially mismatched related donors. Bone Marrow Transplantation, 21(5), 461-471.. © Bone Marrow Transplantation, 1998, Nature Publishing Group. ...
Autologous bone marrow or stem cell transplantation has had an important role in the treatment of aggressive lymphoma for several decades. The important results of the PARMA study1 demonstrated that patients in first relapse who remained chemosensitive had improved progression-free and overall survival compared to patients who continued to receive standard-dose salvage therapy. Based on that trial, salvage autologous bone marrow transplantation became the standard of care for these patients and resulted in a long-term progression-free survival rate of approximately 50%.. Consolidation Strategy. If salvage bone marrow transplantation is effective, would consolidation bone marrow transplantation immediately after initial chemotherapy further improve the survival of advanced-stage, aggressive lymphomas? Over the past 2 decades, numerous randomized studies demonstrated no improvement in overall survival when all patients received consolidative autologous bone marrow transplantation or stem cell ...
Hematopoietic Cell Transplantation, 2nd ed. Blackwell Science, London, 1999, pp. 823-834. 3. Forman SJ, Krance RA, ODonnell MR, et al. Bone marrow transplantation for acute nonlymphoblastic leukemia during first complete remission. An analysis of prognostic factors. Transplantation 1987;43:650-653. 4. Mehta J, Powles R, Treleaven J, et al. Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088. 59. Appelbaum FR, Anderson J. Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia 1998;12 (suppl. 1):S25-S29. Chapter 2 / Allogeneic BMT for AML 27 60. Fefer A. Graft-versus-tumor responses. In: Thomas ED, Blume KG, Forman SJ, eds. Hematopoietic Cell Transplantation, 2nd ed. Blackwell ...
The Pediatric Bone Marrow Transplant program at Childrens Hospital Colorado offers the regions only dedicated bone marrow transplant program for kids.
The Pediatric Bone Marrow Transplant program at Childrens Hospital Colorado offers the regions only dedicated bone marrow transplant program for kids.
Health, ...LEXINGTON Ky. (Aug. 23 2011) Bone marrow transplantation with genet...Bone marrow a spongy tissue inside bones contains stem cells that pr...Par-4 (also known as PAWR) is a tumor suppressor protein that selectiv...After transplantation the researchers discovered the expression of ca...,Bone,marrow,transplantation,may,increase,cancer,resistance,in,patients,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
In two situations, transfer of normal unsensitized bone marrow cells into heavily irradiated H-2-identical allogeneic mice caused a high incidence of lethal chronic graft-versus-host disease (GVHD), i.e. mortality occuring between days of 20 and 80 postirradiation. Minor histocompatibility determinants appeared to be the main target for eliciting GVHD. Removing mature T cells from the marrow with anti-Thy 1.2 serum and complement before injection prevented GVHD. On the basis of adding purified T cells to T-cell-depleted marrow cells, it was concluded that contamination of the marrow with as few as 0.3% T cells was sufficient to cause a high incidence of lethal GVHD in certain situations. No GVHD was found with the injection of non-T cells (Thy 1.2-negative cells) or with tolerant T cells. Irradiated recipients of T-cell-depleted marrow cells remained in good health for prolonged periods. These mice showed extensive chimerism with respect to the donor marrow, normal numbers of T and B cells and ...
P220 To determine the degree and extent of changes in cellular metabolic demand after stroke and bone marrow cell transplantation, a histochemistry assay of cytochrome oxidase (COx) which correlates with neuronal activity was employed,. Adult Wistar rats (n=9) were subjected to transient (2 h) middle cerebral artery occlusion (MCAo). At 1 d after ischemia, bone marrow stromal cells (MSCs, 4x105 in 10 :l) were transplanted intracerebrally into the ischemic boundary zone in the striatum and the cortex. The ischemia rats with (n=4) or without (n=5) MSC transplantation were sacrificed at 14 d after MCAo. Bone marrow cells were harvested from normal donor adult rats and cultured in Iscove s Modified Dulbecco s medium supplemented with 10% fetal bovine serum. MSCs were isolated by their adherence to the plastic dishes from the whole bone marrow cells at 72 h of incubation. Subsequently, the MSCs were cultured for 2 weeks and bromodeoxyuridine (BrdU, as a tracer to identify cells derived from bone ...
TY - JOUR. T1 - Predictors of PTSD in mothers of children undergoing bone marrow transplantation. T2 - The role of cognitive and social processes. AU - Manne, Sharon. AU - DuHamel, Katherine. AU - Nereo, Nancy. AU - Ostroff, Jamie. AU - Parsons, Susan. AU - Martini, Richard. AU - Williams, Sharon. AU - Mee, Laura. AU - Sexson, Sandra Griffin Bishop. AU - Wu, Lisa. AU - Difede, Joanne. AU - Redd, William H.. PY - 2002/10/1. Y1 - 2002/10/1. N2 - Objective: To investigate the role of cognitive and social processing in posttraumatic stress symptoms and disorder (PTSD) among mothers of children undergoing bone marrow and hematopoietic stem-cell transplantation (BMT/SCT). Method: Questionnaires assessing emotional distress, BMT-related fears, and negative responses of family and friends were completed by 90 mothers at the time of the BMT infusion and 3 and 6 months post-BMT. PTSD symptoms were measured 6 months post-BMT by both paper-and-pencil and structured interview methods. Results: Emotional ...
At the University of Chicago Medicine, we offer the full range of blood and bone marrow stem cell transplantation options. We are recognized for our expertise in alternative donor transplantation; relapse prevention and treatment; transplantation for older adults; and focused, disease-specific care.
Bone marrow transplantation is a treatment method used to treat diseases like cancer and thalassemia. This article provides an incite of the techniques and procedures followed for bone marrow transplantation, benefits and risks accompanied by this ...
View details of top bone marrow transplantation hospitals in Westend Heights, Gurgaon, Gurgaon. Get guidance from medical experts to select best bone marrow transplantation hospital in Westend Heights, Gurgaon
View details of top bone marrow transplantation hospitals in Moolchand, New Delhi. Get guidance from medical experts to select best bone marrow transplantation hospital in Moolchand
For some patients, bone marrow transplants become necessary because of several reasons. It could be because of some severe blood disorders including certain types of blood cancers like leukemia and lymphoma. Further, many people have to go in for high-dose chemotherapy. These high dosages may be quite effective in getting rid of dangerous cancer cells. However, they also wipe out healthy cells and in many cases, the entire bone marrow is wiped out and destroyed. In such situations, the only option is to go in for a bone marrow transplant. When a person needs high dosage chemotherapy, often doctors go in for bone marrow transplant to replace the destroyed bone marrow with new ones. This will help the patients to ensure that after the therapy, the body gets high quality and fresh bone marrow. The same can be used for the production of high-quality blood stem cells from the blood cancer bone marrow transplant. This will help in augmenting the supply of red blood cells, white blood cells, and ...
Hello everybody, I have been called out to this study next month and I am very excited it is finally here. I am looking to get any input from the knowledgeable people on this site as to anything that will ...